Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference


Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome


Crinetics announces positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome.

Crinetics Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new non-executive employees

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences


Crinetics management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference on November 28 and the Piper Sandler 35th Annual Healthcare Conference on November 30.

Crinetics Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new non-executive employees